Genomics PLC Announces Positive Results from HEART Study on Precision Cardiovascular Disease Risk Prediction

Genomics plc, a leader in genomics-based healthcare, today announced positive results from its HEART study, which evaluated the clinical utility of its genomics-based cardiovascular disease risk prediction tool.

Key Findings:

• The HEART study enrolled over 100,000 participants and followed them for an average of five years.
• The study found that the Genomics plc risk prediction tool was able to identify individuals at high risk of cardiovascular disease with high accuracy.
• The tool was able to predict the risk of cardiovascular disease events, including heart attack, stroke, and heart failure with 70% accuracy.
• The tool was also able to identify individuals who would benefit from preventive therapies, such as cholesterol-lowering medications and lifestyle changes.

Implications for Clinical Practice:

• The HEART study results suggest that Genomics plc's risk prediction tool can be used to identify individuals at high risk of cardiovascular disease who would benefit from preventive therapies.
• The tool can also be used to guide treatment decisions for individuals who have already been diagnosed with cardiovascular disease.
• The tool can help clinicians to personalize care for their patients and improve outcomes.

Commercialization Plans:

• Genomics plc plans to commercialize its risk prediction tool through its partnerships with healthcare providers and insurers.
• The tool will be available to clinicians through a secure online platform.
• Genomics plc believes that its risk prediction tool has the potential to significantly improve the prevention and treatment of cardiovascular disease.

About Genomics plc:

Genomics plc is a leading genomics-based healthcare company. The company develops and commercializes a range of products and services that use genomics to improve human health. Genomics plc's mission is to make genomics a routine part of healthcare, enabling people to live longer, healthier lives.

For more information on Genomics plc, please visit the company's website at www.genomics.com.